Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. Their most advanced product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2…More, a central node in the RAS signaling pathway. In collaboration with their partner, Sanofi, they are evaluating RMC-4630 in a multi-cohort Phase 1/2 clinical program for a range of tumor types featuring specific oncogenic mutations. Additionally, they are developing a portfolio of mutant-selective RAS inhibitors that they believe are the first potent, selective, cell-active inhibitors of the active, GTP-bound form of RAS, or RAS(ON). Their pipeline also includes inhibitors of other frontier oncology targets within the RAS and mTOR pathways. These include SOS1 and 4EBP1/mTORC1, with a development candidate for the latter, RMC-5552, currently advancing into IND-enabling studies.